2011
DOI: 10.1165/rcmb.2010-0267oc
|View full text |Cite
|
Sign up to set email alerts
|

A Sphingosine 1–Phosphate 1 Receptor Agonist Modulates Brain Death–Induced Neurogenic Pulmonary Injury

Abstract: Lung transplantation remains the only viable therapy for patients with end-stage lung disease. However, the full utilization of this strategy is severely compromised by a lack of donor lung availability. The vast majority of donor lungs available for transplantation are from individuals after brain death (BD). Unfortunately, the early autonomic storm that accompanies BD often results in neurogenic pulmonary edema (NPE), producing varying degrees of lung injury or leading to primary graft dysfunction after tran… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
5
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 29 publications
1
5
0
Order By: Relevance
“…Thus, there is a need to study the mechanism of lung injury after BD and to develop effective therapeutics to decrease lung injury. In the present study, a decrease in the arterial oxygenation index and an increase in the left lung wet/dry weight ratio and the aggravation of lung pathological injury were observed after BD in rats, in accordance with published results describing the lung after BD (35,36).…”
Section: Discussionsupporting
confidence: 93%
“…Thus, there is a need to study the mechanism of lung injury after BD and to develop effective therapeutics to decrease lung injury. In the present study, a decrease in the arterial oxygenation index and an increase in the left lung wet/dry weight ratio and the aggravation of lung pathological injury were observed after BD in rats, in accordance with published results describing the lung after BD (35,36).…”
Section: Discussionsupporting
confidence: 93%
“…S1P can prevent neutrophil chemotaxis and the transmigration of neutrophils across an endothelial cell monolayer [27]. In ALI animal models, administration of S1PR agonists inhibited early pro-inflammatory cytokine production, inhibited innate immune cell recruitment and attenuated inflammatory lung injury [14,[28][29][30][31].…”
Section: Discussionmentioning
confidence: 99%
“…Accordingly, interest in S1P analogs, which similarly confer vascular protection but may have more favorable safety profiles, led to the study of these molecules in our RILI model. These include FTY720, which admittedly has safety concerns of its own, as well as SEW-2871, an S1PR1 agonist, and tyspinate, a phosphonate S1P analog, all three of which have demonstrated protective effects in pre-clinical ALI models [9,16,26,27].…”
Section: Therapeutic Potential Of Direct Targeting Of Sphingolipid Pathways In Rili Rili Protection By S1p Analogsmentioning
confidence: 99%